Indoco Remedies receives USFDA approval for Lacosamide Tablets

Indoco Remedies Ltd has announced the receipt of final approval from the United States Food & Drug Administration (USFDA) for Lacosamide Tablets USP 50 mg, 100 mg, 150 mg and 200 mg, the generic version of Vimpat® Tablets of UCB, Inc.

Lacosamide Tablets are indicated for the prevention and control of seizures. It is an anticonvulsant / antiepileptic drug.

Commenting on the development, Ms. Aditi Kare Panandikar, Managing Director - Indoco Remedies said, "The ANDA approval for Lacosamide Tablets on the day of patent expiry, reverberates our enduring commitment to make quality and affordable generic medicines available to more patients in the United States. Our first shipment of Lacosamide Tablets has already reached US".

According to IQVIA sales data for the period ending January 2022, Vimpat Tablets market achieved annual sales of approx. USD 1.7 billion.

Shares of Indoco Remedies Limited was last trading in BSE at Rs. 409.55 as compared to the previous close of Rs. 390.75. The total number of shares traded during the day was 13514 in over 1276 trades.

The stock hit an intraday high of Rs. 414.35 and intraday low of 388.30. The net turnover during the day was Rs. 5435335.00.

Source : Equity Bulls

Keywords

IndocoRemedies INE873D01024 FinalApproval USFDA LacosamideTablets Vimpat GenericVersion